M.D. Anderson Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).

2,692 total trials 549 currently recruiting 1201 completed early-phase tilt top decile by trial count

M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.

M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.

Top-decile sponsor footprint

M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,692 total, page 25 of 54

COMPLETED NA

Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic Leukemia

NCT04774744
TERMINATED Phase 2

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

NCT04310397
COMPLETED Phase 1

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

NCT03989466
COMPLETED NA

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

NCT04132843
COMPLETED NA

Effect of EHealth Coaching Program on Patient Reported Outcomes of Men With Prostate Cancer

NCT04106245
TERMINATED Phase 1

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04019288
COMPLETED Phase 2

Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer

NCT03830164
COMPLETED Phase 2

Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers

NCT04082572
TERMINATED Phase 2

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

NCT03856216
COMPLETED Phase 1

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

NCT03417284
COMPLETED NA

Optiflow THRIVE for Delivery of Oxygen to Patients During Total Intravenous Anesthesia While Undergoing Radiology Procedures

NCT04171037
TERMINATED Phase 2

Early Metabolic Resuscitation for Septic Shock

NCT03895853
TERMINATED Phase 1

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

NCT04160052
TERMINATED Phase 2

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

NCT03872388
TERMINATED Phase 4

An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer

NCT04134208
COMPLETED Phase 1

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

NCT03259503
COMPLETED Phase 1

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT04022785
TERMINATED Phase 2

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT04047797
COMPLETED NA

Project Self in Improving Cervical Cancer Screening Rates in Hispanic and African American Women

NCT04614155
COMPLETED

Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer

NCT04087057
COMPLETED

Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

NCT04257045
COMPLETED Phase 1

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

NCT04021043
TERMINATED Phase 1

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

NCT02757391
COMPLETED NA

Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer

NCT04022772
COMPLETED

4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer

NCT05130073
COMPLETED Phase 1

A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors

NCT03784677
COMPLETED Phase 2

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

NCT03990571
COMPLETED NA

An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer

NCT04022746
COMPLETED Phase 1

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

NCT03207529
TERMINATED Phase 2

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

NCT04256941
COMPLETED NA

F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery

NCT03926507
COMPLETED Early Phase 1

Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease

NCT03868020
TERMINATED Early Phase 1

Safety of MRI Compatible Hardware for MRI-based Image Guidance During Spine Surgery

NCT04563806
TERMINATED Phase 1

Dietary Intervention in Patients with a History of Melanoma

NCT03950635
COMPLETED NA

Ultrasound in Evaluating Muscle-Glycogen Content in Cancer Patients

NCT03982082
TERMINATED Phase 2

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

NCT04066894
TERMINATED Phase 2

Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

NCT03622775
COMPLETED NA

Scrambler Therapy for the Reduction of Chemotherapy-Induced Neuropathic Pain

NCT04239976
COMPLETED Phase 1

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

NCT03581487
COMPLETED NA

Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits

NCT03856060
COMPLETED

Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings

NCT04186884
COMPLETED Phase 1

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT03756818
COMPLETED Phase 2

MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)

NCT03469284
COMPLETED Phase 2

Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery

NCT03745794
COMPLETED Phase 2

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

NCT03873818
COMPLETED Phase 2

Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

NCT03770416
TERMINATED Phase 1

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

NCT03735875
TERMINATED Phase 2

Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations

NCT03740100
COMPLETED Phase 1

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

NCT03725436
COMPLETED NA

Feasibility of Laryngeal Mask Airway Gastro on Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Pancreas and Bile Duct Disorders

NCT03775681
← Previous Page 25 of 54 Next →

Phase Distribution

PhaseTrial count
Phase 1 748
Phase 2 971
Phase 3 96
Phase 4 28

Therapeutic Areas

Hematopoietic and Lymphoid Cell Neoplasm 44
Malignant Solid Neoplasm 42
Breast Cancer 41
Acute Myeloid Leukemia 38
Leukemia 37
Myelodysplastic Syndrome 33
Lymphoma 32
Cancer 31
Recurrent Acute Myeloid Leukemia 25
Lung Cancer 23

What is open in the M.D. Anderson Cancer Center pipeline

549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).

Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).

Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.